Overview

Corporate Profile

T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.



Stock Quote
TTOO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$6.68
Change (%)0.00 (0.00%)
Volume11,993
Data as of 08/30/16 10:34 a.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
08/04/16T2 Biosystems to Present at the Canaccord Genuity Growth Conference
LEXINGTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that John McDonough, president and chief executive officer, and Shawn Lynch, chief financial officer, are scheduled to attend and present at the Canaccord Genuity Growth Conference on Thursday, August 11, 2016, at 8:30 a.m. ET in Boston. A live, listen-only webcast of the presentation may be accessed by visiting the Investors/Events & Presentations section of the Company’s website at ww... 
Printer Friendly Version
08/01/16T2 Biosystems Reports 2016 Second Quarter, Six-Month Results
LEXINGTON, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today reported operating highlights and financial results for the second quarter and six months ended June 30, 2016.  Recent operational highlights included: During the second quarter, the Company received commitments for the adoption of the T2Candida® Panel and the T2Dx® Instrument with four new hospitals and hospital syst... 
Printer Friendly Version
07/21/16T2 Biosystems Announces 2016 Second Quarter and Six-Month Results Release and Conference Call Date
LEXINGTON, Mass., July 21, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced that it will release its 2016 second quarter and six-month financial results after the market closes on Monday, August 1, 2016.  In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, August 1, 2016, to discuss the financial results and other business developments. Interested parties may access the live cal... 
Printer Friendly Version
07/18/16T2 Biosystems Announces Research and Development Collaboration with Bayer to Advance Drug Monitoring and Biomarker Discovery for Blood Coagulation Disorders
LEXINGTON, Mass., July 18, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, has signed a multi-year agreement to provide T2 Biosystems’ T2 Magnetic Resonance technology platform, or T2MR®, for Bayer’s research and development efforts in blood coagulation disorders. This collaboration will develop tools and evaluate assays to help drive drug discovery and biomarker research for select Bayer hemostasis-rela... 
Printer Friendly Version

More News

Investor Contact Information
Contact: ir@T2Biosystems.com
(781) 761-4646
Data provided by Nasdaq. Minimum 15 minutes delayed.